نبذة مختصرة : An unfavorable prognosis for ovarian cancer is associated with metastasis to the peritoneum and the formation of malignant ascites, which contains factors affecting the growth and survival of tumor cells. Molecular and functional analysis of ascites provides information both for clinical diagnosis and for understanding the mechanisms of progression and resistance in ovarian cancer. The aim of the study was to evaluate the levels of IL-8 and WISP1 in the acellular portion of ascites in advanced ovarian cancer. In 30 patients diagnosed with ascitic ovarian cancer stage III-IV according to FIGO, before treatment, the levels of IL-8 (Kit A-8762, Interleukin-8-ELISA-BEST, JSC Vector-Best, Russia) and WISP1 (Kit SEG895Hu CloudClone Corp., China) were determined (pg/mL). Based on the results of the effectiveness of chemotherapy according to the TP scheme, all patients were divided into the following groups: without relapse, relapse-free period up to 6 months – early relapse and progression during chemotherapy. Statistical processing was carried out using Statistica 13. Analysis of patient progression-free time was carried out using the Cox regression method, and the patient survival function was assessed using the Kaplan-Meier method (Jamovi 2.4.14). We found that the level of IL-8 in the acellular part of malignant ascites in ovarian cancer in patients without relapse is significantly lower than in the early relapse group (176.58 (139.68-217.01) pg/mL versus 320.43 pg/mL (250.49-369.81), p = 0.019). The level of WISP1 was significantly increased in the acellular part of ascites only in patients with progression during chemotherapy (980.51 (796.61-1524.15) pg/mL versus 770.55 (500.60- 1254.90) pg/mL in patients without relapse and 764.09 (581.55-823.38) pg/mL in patients with relapse). We found a positive strong Pearson correlation between IL-8 and WISP1 in ascites in a group of patients without relapse (r = 0.783, p = 0.012). In the multivariate version of Cox regression, the risk of relapse increases by 1.01 ...
Relation: https://www.mimmun.ru/mimmun/article/view/3051/1978; Алешикова О.И., Антонова И.Б., Бабаева Н.А. Динамика цитокинового профиля в асците при распространенном раке яичников // Акушерство и гинекология: новости, мнения, обучение. 2019. Т. 7, № 1. C. 16-23.; Abell S.K., De Courten B., Boyle J.A., Teede H.J. Inflammatory and other biomarkers: role in pathophysiology and prediction of gestational diabetes mellitus. Int. J. Mol. Sci., 2015, Vol. 16, pp.13442-13473.; Antony F., Deantonio C., Cotella D., Soluri M.F., Tarasiuk O., Raspagliesi F., Adorni F., Piazza S., Ciani Y., Santoro C., Macor P., Mezzanzanica D., Sblattero D. High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. Oncoimmunology, 2019, Vol. 8, no. 9, e1614856. doi:10.1080/2162402X.2019.1614856.; Barchetta I., Cimini F.A., De Gioannis R., Ciccarelli G., Bertoccini L., Lenzi A., Baroni M.G., Cavallo G. Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without nonalcoholic liver disease. Diabetes Metab. Res. Rev., 2018, Vol. 34, no. 5, e2998. doi:10.1002/dmrr.2998.; Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018. Vol. 68, no. 6, pp. 394-424.; Brigstock D.R. The CCN family: a new stimulus package. J. Endocrinol., 2003. Vol. 178, pp. 169-175.; Chang A.C., Lien M.Y., Tsai M.H., Hua C.H., Tang C.H. WISP-1 promotes epithelial-mesenchymal transition in oral squamous cell carcinoma cells via the miR-153-3p/Snail Axis. Cancers (Basel), 2019, Vol. 11, no. 12, 1903. doi:10.3390/cancers11121903.; Jones V.S., Huang R.Y., Chen L.P., Chen Z.S., Fu L., Huang R.P. Cytokines in cancer drug resistance: Cues to new therapeutic strategies. Biochim. Biophys. Acta, 2016, Vol. 1865, no. 2, pp. 255-265.; Jun J.I., Lau L.F. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat. Rev. Drug Discov., 2011, Vol. 10, pp. 945-963.; Krugmann J., Schwarz C.L., Melcher B., Sterlacci W., Ozalinskaite A., Lermann J., Agaimy A., Vieth M. Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015. Arch. Gynecol. Obstet., 2019. Vol. 299, no. 2, pp. 515-523.; Li Y., Wang F., Liu T., Lv N., Yuan X., Li P. WISP1 induces ovarian cancer via the IGF1/αvβ3/Wnt axis. J. Ovarian Res., 2022, Vol. 15, no. 1, 94. doi:10.1186/s13048-022-01016-x.; Rickard B.P., Conrad C., Sorrin A.J., Ruhi M.K., Reader J.C., Huang S.A., Franco W., Scarcelli G., Polacheck W.J., Roque D.M., Del Carmen M.G., Huang H.C., Demirci U., Rizvi I. Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers (Basel), 2021, Vol. 13, no. 17, 4318. doi:10.3390/cancers13174318.; Tsai H.C., Tzeng H.E., Huang C.Y., Huang Y.L., Tsai C.H., Wang S.W., Wang P.C., Chang A.C., Fong Y.C., Tang C.H. WISP-1 positively regulates angiogenesis by controlling VEGF-A expression in human osteosarcoma. Cell Death Dis., 2017, Vol. 8, no. 4, e2750. doi:10.1038/cddis.2016.421.; Wen J., Zhao Z., Huang L, Wang L., Miao Y., Wu J. IL-8 promotes cell migration through regulating EMT by activating the Wnt/β-catenin pathway in ovarian cancer. J. Cell. Mol. Med., 2020. Vol. 24, no. 2, pp. 1588-1598.; Wróblewski M., Szewczyk-Golec K., Hołyńska-Iwan I., Wróblewska J., Woźniak A. Characteristics of selected adipokines in ascites and blood of ovarian cancer patients. Cancers (Basel), 2021, Vol. 13, no. 18, 4702. doi:10.3390/cancers13184702.; https://www.mimmun.ru/mimmun/article/view/3051
Processing Request
No Comments.